Literature DB >> 20034580

The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.

Mitul A Mehta1,2,3, Oliver D Howes1,2,3, Alice Egerton1,2,3, Arsime Demjaha1,3, Philip McGuire3.   

Abstract

Brain presynaptic dopaminergic function can be assessed using 18F-DOPA positron emission tomography (PET). Regional 18F-DOPA utilization may be used to index dopaminergic abnormalities over time or dopaminergic response to treatment in clinical populations. Such studies require prior knowledge of the stability of the 18F-DOPA signal in the brain regions of interest. Test-retest reliability was examined in eight healthy volunteers who each received two 18F-DOPA PET scans, approximately 2 years apart. 18F-DOPA utilization (k(i)(cer)) was determined using graphical analysis relative to a reference tissue input (Patlak and Blasberg, 1985). Reproducibility (measured as the within-subjects variation) and reliability (measured as intraclass correlation coefficients, ICCs) of 18F-DOPA k(i)(cer) were assessed in the structural and functional subdivisions of the striatum and select extrastriatal brain regions. Voxel-based median ICC maps were used to visualize the distribution of 18F-DOPA k(i)(cer) reliability across the brain. The caudate and putamen, and associative and sensorimotor, striatal subdivisions showed good reliability across the two scan sessions with bilateral ICCs ranging from 0.681 to 0.944. Reliability was generally lower in extrastriatal regions, with bilateral ICCs ranging from 0.235 in the amygdala to 0.894 in the thalamus. These data confirm the utility of 18F-DOPA PET in assessing dopaminergic function in the striatum and select extrastriatal areas but highlight the limitations in using this approach to measure dopaminergic function in low uptake extrastriatal brain areas. This information can be used to optimize the experimental design of future studies investigating changes in brain dopaminergic function with 18F-DOPA. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20034580      PMCID: PMC4096947          DOI: 10.1016/j.neuroimage.2009.12.058

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  53 in total

1.  Multiresolution analysis of emission tomography images in the wavelet domain.

Authors:  F E Turkheimer; M Brett; D Visvikis; V J Cunningham
Journal:  J Cereb Blood Flow Metab       Date:  1999-11       Impact factor: 6.200

2.  Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo.

Authors:  E H Danielsen; D Smith; F Hermansen; A Gjedde; P Cumming
Journal:  Synapse       Date:  2001-08       Impact factor: 2.562

Review 3.  On the rate of decarboxylation of dopa to dopamine in living mammalian brain.

Authors:  P Cumming; P Deep; O Rousset; A Evans; A Gjedde
Journal:  Ann N Y Acad Sci       Date:  1997-12-19       Impact factor: 5.691

4.  Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum.

Authors:  Diana Martinez; Mark Slifstein; Allegra Broft; Osama Mawlawi; Dah-Ren Hwang; Yiyun Huang; Thomas Cooper; Lawrence Kegeles; Eric Zarahn; Anissa Abi-Dargham; Suzanne N Haber; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2003-03       Impact factor: 6.200

5.  Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum.

Authors:  O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2001-09       Impact factor: 6.200

6.  Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus.

Authors:  A Brück; R Portin; A Lindell; A Laihinen; J Bergman; M Haaparanta; O Solin; J O Rinne
Journal:  Neurosci Lett       Date:  2001-09-28       Impact factor: 3.046

7.  Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease.

Authors:  T Nakamura; V Dhawan; T Chaly; M Fukuda; Y Ma; R Breeze; P Greene; S Fahn; C Freed; D Eidelberg
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

8.  Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity.

Authors:  J Tedroff; R Torstenson; P Hartvig; C Sonesson; N Waters; A Carlsson; H Neu; K J Fasth; B Långström
Journal:  Synapse       Date:  1998-04       Impact factor: 2.562

Review 9.  Imaging end points for monitoring neuroprotection in Parkinson's disease.

Authors:  David J Brooks
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

10.  Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.

Authors:  Gerhard Gründer; Ingo Vernaleken; Matthias J Müller; Eugen Davids; Nilufar Heydari; Hans-Georg Buchholz; Peter Bartenstein; Ole L Munk; Peter Stoeter; Dean F Wong; Albert Gjedde; Paul Cumming
Journal:  Neuropsychopharmacology       Date:  2002-10-30       Impact factor: 7.853

View more
  52 in total

1.  Towards PET imaging of intact pancreatic beta cell mass: a transgenic strategy.

Authors:  Rebecca McGirr; Shirley Hu; Siu-Pok Yee; Michael S Kovacs; Ting-Yim Lee; Savita Dhanvantari
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

2.  Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.

Authors:  Oliver D Howes; Paul Shotbolt; Michael Bloomfield; Kirstin Daalman; Arsime Demjaha; Kelly M J Diederen; Kemal Ibrahim; Euitae Kim; Philip McGuire; René S Kahn; Iris E Sommer
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

3.  Ventral striatal dopamine reflects behavioral and neural signatures of model-based control during sequential decision making.

Authors:  Lorenz Deserno; Quentin J M Huys; Rebecca Boehme; Ralph Buchert; Hans-Jochen Heinze; Anthony A Grace; Raymond J Dolan; Andreas Heinz; Florian Schlagenhauf
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

Review 4.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

5.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

6.  Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with ¹⁸F-dopa brain PET in normal controls and patients with Parkinson's disease.

Authors:  Liane Oehme; Maria Perick; Bettina Beuthien-Baumann; Martin Wolz; Alexander Storch; Matthias Löhle; Birgit Herting; Jens Langner; Jörg van den Hoff; Heinz Reichmann; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

7.  Methylphenidate boosts choices of mental labor over leisure depending on striatal dopamine synthesis capacity.

Authors:  Lieke Hofmans; Danae Papadopetraki; Ruben van den Bosch; Jessica I Määttä; Monja I Froböse; Bram B Zandbelt; Andrew Westbrook; Robbert-Jan Verkes; Roshan Cools
Journal:  Neuropsychopharmacology       Date:  2020-09-12       Impact factor: 7.853

8.  Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.

Authors:  Joel T Dunn; Chloe Clark-Papasavas; Paul Marsden; Stacey Baker; Marcel Cleij; Shitij Kapur; Robert Kessler; Robert Howard; Suzanne J Reeves
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-17       Impact factor: 6.200

9.  The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

Authors:  Oliver D Howes; Joseph Kambeitz; Euitae Kim; Daniel Stahl; Mark Slifstein; Anissa Abi-Dargham; Shitij Kapur
Journal:  Arch Gen Psychiatry       Date:  2012-08

10.  The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study.

Authors:  Enrico D'Ambrosio; Tarik Dahoun; Antonio F Pardiñas; Mattia Veronese; Michael A P Bloomfield; Sameer Jauhar; Ilaria Bonoldi; Maria Rogdaki; Sean Froudist-Walsh; James T R Walters; Oliver D Howes
Journal:  Psychiatry Res Neuroimaging       Date:  2019-07-19       Impact factor: 2.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.